ホームページへ
4.6/5
TrustPilot

エルサレムで最高の乳癌化学療法医師 - トップ3名の医師

イスラエルのトップ乳癌化学療法医師と価格を比較。こちらで最適なマッチングを見つけてください

イスラエル
エルサレム

イスラエルの3名のトップ乳癌化学療法専門家から見積もりを取得

ご要望と予算に基づいて最適な医師を厳選いたします

医学的監修者 Fahad Mawlood

医学編集者・データサイエンティスト

トップ医師

3

イスラエル

レビュー

14000+

実際の患者より

医師サービスで最良価格の国を選択

トップ各国の乳癌化学療法価格を比較

国をタップしてトップ医師と価格を表示

Ukraine
Turkey
Mexico
Thailand
Czech Republic
Poland
$1,200 - $2,500
$1,200 - $3,500
$2,000 - $5,000
$3,000 - $7,000
$3,000 - $6,000
$3,500 - $6,500
$0
$2,000
$4,000
$6,000

個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし

Tamar Jablonski-Perec

  • 所在地： イスラエル, エルサレム
  • クリニック：
    4.2
    Hadassah Medical Center

  • Tamar Jablonski-Perec is an oncologist at the Hadassah Medical Center who received her Doctor of Medical Sciences at the Hebrew University in Jerusalem and completed an internship at the renowned Sloan-Kettering Cancer Center in New York. Her key takeaways include:

    • Head of Institute of Oncology in 1994
    • Head of Breast Cancer Treatment Center in 1998
    • Professor of the Department of Oncology at the Hebrew University in 2006
    • Member of several international cancer communities
    • Awarded a scholarship from the Hadassah Medical School
  • 続きを読む
診察
お問い合わせください

Luna Kaduri

  • 31年の経験
  • 所在地： イスラエル, エルサレム
  • クリニック：
    4.2
    Hadassah Medical Center

  • RESEARCH ACTIVITY

    1998–2000 — Conducted research on the genesis of cancer at The Royal Marsden Hospital (England).

    PUBLICATIONS

    Authored numerous peer-reviewed articles in scientific journals. Selected topics include:

    Oncotype Dx Recurrence Score in BRCA1/2 germline mutation carriers with hormone receptor-positive breast cancer.

    TP53 missense mutation recurrence in cancer patients of Arab descent.

    Adjuvant autologous vaccine for stage III microscopic melanoma: biomarker survival and enhanced response to CTLA-4 blockade.

    Prognostic significance of (R)CA15-3 assay in primary breast cancer.

    Diagnostic and prognostic value of comparative thymidine kinase 1 (TK1) activity assays in breast cancer patient serum.

    Complete remission in a BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma treated with cisplatin.

    Autologous vaccine-induced antitumor and self-reactive immune responses in melanoma: impact on patient survival and dependence on MHC class II expression.

    PROFESSIONAL AFFILIATIONS

    Israeli Society of Clinical Oncology

    Israel Medical Association

    AWARDS & GRANTS

    Cancer Genetics Research Foundation Award

    Landau Prize

    Judith Segal Memorial Award

  • 続きを読む
診察
お問い合わせください

Beatrice Uziely

  • 37年の経験
  • 認定:
  • 所在地： イスラエル, エルサレム
  • クリニック：
    4.2
    Hadassah Medical Center

  • ドクター・ベアトリス・ウジエリは、イスラエルを拠点とした、放射線腫瘍学の専門家である癌のスペシャリストです。11の助成金受賞者。乳癌、転移治療、ホルモン療法および化学療法の適用を専門としています。

    職務経験

    • 2001年から — ハダサ医療センターの腫瘍学部門の責任者
    • 1992-2001 — ハダサ医療センターのシニア医師
    • 1992 — 研究員、USC/Norris Cancer Center (USA)。
    • 1989-1992 — ハダサ-ヘブライ大学医療センターのシャーレット腫瘍学研究所のシニア医師。

    学歴

    • 1975 — エルサレムヘブライ大学 — 生物学の学位
    • 1981 — エルサレムヘブライ大学 — 医学の学位
    • 1989 — エルサレムヘブライ大学 — 腫瘍学および放射線腫瘍学の専門。

    教育活動

    • 1999年から — エルサレムヘブライ大学での医学腫瘍学および放射線腫瘍学の臨床シニア講師
    • 1994-1999 — エルサレムヘブライ大学での医学腫瘍学および放射線腫瘍学の講師。

    科学活動

    • 癌研究に捧げられた59件の出版物の著者。
    • 癌研究に関する11の助成金を持つ。

    所属学会

    • イスラエル医師会
    • イスラエル臨床腫瘍学・放射線療法学会
    • アメリカ臨床腫瘍学会
    • ヨーロッパ臨床腫瘍学会。
  • 続きを読む
診察
お問い合わせください

海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。

ヤン・マツィイフスキー

医療コーディネーターチーム責任者

4300+件以上の患者の旅をガイド

Bookimedで3年

Israelの142名の患者が今月当社を通じて医師を見つけました

完璧な医師マッチングを取得する方法

1

2分のクイズ

目標、予算、スケジュールをお聞かせください

2

人間のマッチング + AI

アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します

3

オプション準備完了

価格、パッケージ、日程を比較。コーディネーターとチャット

選択肢に迷っていますか？

専属の Bookimedコーディネーターがお客様のニーズに合わせた完璧な外科医を見つけるお手伝いをします

  • すべての段階で24時間365日サポート
  • 医師とのマッチングサポートとクリニックとの全てのコミュニケーションを処理
  • 旅行、宿泊、送迎を調整します

治療をガイド

医療訓練を受けた専属コーディネーター

Peguy Beaugris
Tetyana Hyrych
Zekra Eldeeb
Victoria Olayinka
Iryna Sydorchuk
Tetiana Ihnatiuk

適切な医師とクリニックの選び方：内部者のヒント

医師やクリニックを選ぶ際は、これらの重要なポイントを覚えておいてください：
資格を確認
ISAPS、JCI、または関連医学会などの機関からの認証を確認してください
成功率を確認
お客様の特定治療に豊富な経験と実績のある医師をお選びください
患者レビューを読む
実際の患者様のBookimedレビューをご覧になり、体験について学んでください
効果的なコミュニケーションの確保
円滑な治療のため言語サポートを提供するクリニックを選んでください。
サービスについて質問
隠れた費用を避けるため、価格に宿泊、現地送迎、アフターケアなどのサービスが含まれているかご確認ください

Bookimed洞察：イスラエルのトップ乳癌化学療法専門家（2026）

Bookimedはイスラエルの乳癌化学療法リクエスト1件を調整し、3名のトップ評価専門家と協力しています。この表の医師は国際的資格、臨床専門知識、患者の結果に基づいて選ばれています。2026年ランキングは実際の患者ケースとパートナークリニックの現行プログラムからの検証済みデータを使用して形成されています
順位医師経験適合する方特色クリニックと所在地診察

イスラエルでの治療に関するFAQ

これらのFAQはBookimedを通じて医療支援を求める実際の患者からのものです。回答は経験豊富な医療コーディネーターと信頼できるクリニック代表者が行います。

Who are the leading breast cancer oncologists in Israel?

Leading breast cancer oncologists in Israel combine molecular genetics with personalized chemotherapy to improve patient outcomes. Top specialists like Prof. Ofer Merimsky and Dr. Beatrice Uziely hold international fellowships and lead research at JCI-accredited centers. These experts prioritize genomic testing to tailor aggressive treatments for complex cases.

  • Molecular expertise: Dr. Ari Raphael at Sourasky Medical Center leads national genomic medicine initiatives.
  • Academic leadership: Dr. Beatrice Uziely at Hadassah Medical Center has authored over 55 research publications.
  • Advanced training: Dr. Tamar Jablonski-Perec completed specialized training at Memorial Sloan-Kettering Cancer Center.
  • Long-term experience: Dr. Fredi Aviv brings over 30 years of expertise to chemotherapy planning.

Bookimed Expert Insight: Data shows a high concentration of dual-specialized oncologists at Sourasky and Assuta Medical Centers. For instance, Dr. Irina Zhevelyuk and Dr. Irina Stepfansky combine internal medicine with oncology for 25+ years. This allows them to manage chemotherapy side effects while treating the cancer effectively. Patients can access consultations with these experts starting from $750 to $950.

Patient Consensus: Patients note that Israeli oncologists use personalized protocols and early genetic testing to avoid unnecessary treatments. Many were surprised by the meticulous cardiac monitoring required before starting specific chemotherapy cycles. They also appreciate having constant contact with nurses to manage side effects like nausea.

What qualifications do Israeli breast-cancer oncologists have?

Israeli breast cancer oncologists hold medical degrees followed by five years of specialized residency training. Most maintain board certification from the Scientific Council of the Israel Medical Association. Top specialists often complete international fellowships in the US or Europe to master advanced chemotherapy protocols.

  • Specialized training: Doctors complete six years of medical school plus extensive oncology residencies.
  • International fellowships: Many specialists trained at institutions like New York Hospital or Institut Gustave Roussy.
  • Academic leadership: Senior oncologists often serve as professors or lead national specialized cancer divisions.
  • Research expertise: Leading doctors actively participate in global oncology societies and clinical trial groups.

Bookimed Expert Insight: Data shows a trend of dual expertise among top Israeli specialists. For example, Dr. Tamar Sapra at Sourasky Medical Center has 30+ years of experience combining chemotherapy and radiotherapy. This allows for more cohesive treatment plans in one location. Patients often benefit from doctors who hold leadership roles, such as Prof. Ofer Merimsky, who is an Associate Professor and leads a national center.

Patient Consensus: Patients note that doctors are very direct about prognosis and treatment steps. Many appreciate how quickly coordinators organize consultations with specialists who speak fluent English. People were surprised by how daily tumor boards between different doctors made their treatment feel more precise.

How do Israeli doctors decide when chemotherapy is necessary for breast cancer?

Israeli doctors determine the necessity of chemotherapy by integrating advanced genomic profiling with precise tumor biology analysis. Specialized oncologists evaluate hormone receptor status and HER2 protein levels to identify cases where systemic treatment offers the most significant survival benefits.

  • Genomic testing: Doctors use Oncotype DX and Prosigna to analyze 21 specific tumor genes.
  • Biomarker evaluation: Testing for ER, PR, and HER2 receptors confirms if cancer is triple-negative.
  • Recurrence scoring: Low genomic scores help 50% to 70% of early-stage patients skip chemotherapy safely.
  • Risk assessment: Teams consider Ki-67 protein levels and lymph node involvement for recurrence risk.

Bookimed Expert Insight: Data shows a strong trend toward genomic-guided medicine led by experts like Dr. Ari Raphael at Sourasky Medical Center. He moderates a Molecular Tumor Board where specialists use liquid biopsies and national genomic initiatives. This high-level coordination allows doctors to customize chemotherapy cycles, often reducing them to four sessions for low-risk cases.

Patient Consensus: Patients note that fresh biomarker testing during second opinions sometimes reverses initial chemotherapy recommendations. They feel relieved when genomic scores show they can rely on hormone therapy alone. Many emphasize that doctors focus heavily on tumor biology rather than just tumor size.

Can Israeli doctors give chemotherapy before surgery (neoadjuvant therapy)?

Israeli oncologists routinely provide neoadjuvant chemotherapy to shrink tumors before surgery. This strategic approach often allows for breast-conserving lumpectomies instead of full mastectomies. Specialist doctors use genomic profiling to tailor these systemic treatments for aggressive subtypes like triple-negative or HER2-positive breast cancer.

  • Surgical downsizing: Shrinking large tumors increases the likelihood of successful breast-conserving surgery.
  • Systemic clearance: Early treatment targets microscopic cancer cells that may have spread elsewhere.
  • Response monitoring: Doctors observe how the specific tumor reacts to drugs in real time.
  • Pathologic assessment: Achieving a complete response before surgery helps define long-term prognosis.

Bookimed Expert Insight: Data shows that Israeli oncologists often hold dual specializations to refine neoadjuvant plans. For example, Dr. Irina Zhevelyuk at Assuta Medical Center is both an oncologist and a radiologist. This allows for precise coordination between chemotherapy cycles and localized imaging to monitor tumor shrinkage before the surgeon operates.

Patient Consensus: Patients note that starting chemotherapy first does not always mean the cancer is advanced. They feel relieved when scans show the tumor getting smaller before their operation. Many were surprised to find that this strategy could eliminate the need for a mastectomy entirely.

Which chemotherapy protocols do Israeli oncologists commonly use for breast cancer?

Israeli oncologists utilize standardized breast cancer chemotherapy protocols aligned with NCCN and EORTC benchmarks. Common regimens include AC-T for high-risk cases and TCHP for HER2-positive tumors. Experts often integrate genomic profiling and molecular tumor profiling to personalize systemic treatment and maximize success.

  • Adjuvant regimens: AC-T and dose-dense variants are standard to prevent recurrence after surgery.
  • HER2-positive protocols: Specialists frequently use TCHP or AC-THP combinations to shrink aggressive tumors.
  • Genomic-guided therapy: Dr. Ari Raphael at Sourasky uses molecular profiling to tailor chemotherapy dosage.
  • Metastatic treatment: Oncologists apply single-agent options like Capecitabine or Abraxane for advanced stages.

Bookimed Expert Insight: Israeli oncology leads in integrating genomic data into routine care. Dr. Beatrice Uziely at Hadassah Medical Center utilizes molecular profiling to determine if chemotherapy is necessary. This approach allows some patients to avoid intensive systemic treatments entirely while maintaining a high survival rate. Patients can access specialized consultations with Prof. Ofer Merimsky for approximately $950 or Dr. Irina Stepfansky for $750 at Sourasky Medical Center.

Patient Consensus: Patients note that doctors coordinate every step of the journey and provide a clear path forward quickly. Many emphasize that having a dedicated team helps them manage the emotional weight of treatment. They also mention that medical staff often discuss cold caps and fertility preservation before starting the first cycle.

How can a patient obtain a second opinion from an Israeli breast-cancer specialist?

Patients can obtain a second opinion from Israeli breast cancer specialists through remote online consultations or in-person appointments. This process involves submitting medical records to specialized oncology departments for a formal review. Bookimed handles doctor communication and scheduling for these expert assessments.

  • Specialist selection: Bookimed matches patients with oncologists based on their specific cancer type.
  • Medical records: Patients must provide pathology reports, imaging disks, and previous treatment summaries.
  • Consultation delivery: Specialists provide a formal report and treatment plan for local oncology teams.
  • Online access: Many senior professors offer video consultations to international patients within weeks.

Bookimed Expert Insight: Data shows that many top Israeli oncologists, such as Prof. Ofer Merimsky and Dr. Irina Stepfansky, hold dual expertise in internal medicine and research. Their active participation in phase I-III clinical trials often allows them to suggest innovative chemotherapy protocols. These specialists typically work at JCI-accredited facilities like Sourasky Medical Center or Assuta Medical Center. Consultations with these leading experts start from $750 to $950.

Patient Consensus: Patients emphasize the importance of having every pathology report and scan ready before the first call. They noticed that identifying a request specifically for a chemotherapy second opinion helps reach the right oncologist faster. Many noted it felt much easier to have a coordinator handle the tricky logistics and translations.